FDA Okays Pasireotide (Signifor LAR) for AcromegalyFDA Okays Pasireotide (Signifor LAR) for Acromegaly

The long-acting somatostatin analog pasireotide has been approved for the additional indication of treatment of acromegaly in the US, for patients who don't respond well to surgery or first-line agents. FDA Approvals
Source: Medscape Diabetes Headlines - Category: Endocrinology Tags: Diabetes & Endocrinology News Alert Source Type: news

Related Links:

In conclusion, PPT are rare tumors and have been misdiagnosed mainly as non-functioning pituitary adenomas. Different types of PPT share similar epidemiology, clinical manifestations and surgical outcomes. Surgery is the only curative option but complic ations and subtotal resection are common.
Source: Reviews in Endocrine and Metabolic Disorders - Category: Endocrinology Source Type: research
In conclusion, PPT are rare tumors and have been misdiagnosed mainly as non-functioning pituitary adenomas. Different types of PPT share similar epidemiology, clinical manifestations and surgical outcomes. Surgery is the only curative option but complications and subtotal resection are common. PMID: 30864049 [PubMed - as supplied by publisher]
Source: ENDOCR REV - Category: Endocrinology Authors: Tags: Rev Endocr Metab Disord Source Type: research
Abstract Acromegaly is a rare disease caused by excessive production of growth hormone (GH), typically by a pituitary tumour. The diagnosis is usually delayed, and patients frequently develop various complications that cause premature mortality. In patients with hypertension, heart failure, diabetes, and arthropathies that are not age-specific, attention should be paid to signs of acromegaly. Insulin-like growth factor 1 (IGF-1) assay should be used as a screening test whenever acromegaly is suspected. Further diagnostic investigations and treatment should be carried out at specialist centres. First-line treatment...
Source: Endokrynologia Polska - Category: Endocrinology Authors: Tags: Endokrynol Pol Source Type: research
In conclusion, acromegaly registries offer a global view of the disease with no “a priori” assumptions. This is of outmost importance, because of the large amount of data and the huge number of associated comorbidities. This will help to establish guidelines for management of this rare disease.
Source: Best Practice and Research Clinical Endocrinology and Metabolism - Category: Endocrinology Source Type: research
Authors: Chanson P, Vialon M, Caron P Abstract INTRODUCTION: As pregnancy is rare in women with acromegaly, only case reports and few series have been published. Areas covered: All case reports and publications dealing with pregnancy in patients with acromegaly were collated. Information concerning the effects of acromegaly on pregnancy outcomes, the impact of pregnancy on GH/IGF-I measurements, acromegaly comorbidity and pituitary adenoma size, the effects of treatment of acromegaly on fetus outcomes were retrieved and analyzed. Expert commentary: Based on the small number of reported cases, pregnancy is generally...
Source: Expert Review of Endocrinology and Metabolism - Category: Endocrinology Tags: Expert Rev Endocrinol Metab Source Type: research
For patients with acromegaly, 10 years or more may pass from symptom onset before a correct diagnosis is made, by which time complications may already exist. Could you be missing the signs?Medscape Diabetes &Endocrinology
Source: Medscape Internal Medicine Headlines - Category: Internal Medicine Tags: Diabetes & Endocrinology Article Source Type: news
Publication date: March–April 2019Source: Diabetes &Metabolic Syndrome: Clinical Research &Reviews, Volume 13, Issue 2Author(s): Leila Moradi, Fatemeh Amiri, Hajieh ShahbazianAbstractPatients with acromegaly have soft tissue overgrowth that induced characteristic clinical presentation. A growth hormone-secreting adenoma of the anterior pituitary gland is the most common cause of acromegaly. Metabolic and somatic features of acromegaly caused by high serum concentrations of insulin-like growth factor-I (IGF-I) and excess growth hormone (GH) production. we present a case of ‘pseudoacromegaly’ with a...
Source: Diabetes and Metabolic Syndrome: Clinical Research and Reviews - Category: Endocrinology Source Type: research
Conclusions: In contrast to the current consensus criteria, we recommend a more reluctant use of pasireotide LAR therapy for the treatment of acromegaly. PMID: 30608534 [PubMed - as supplied by publisher]
Source: The Journal of Clinical Endocrinology and Metabolism - Category: Endocrinology Authors: Tags: J Clin Endocrinol Metab Source Type: research
We present a case series of 17 pregnancies in 12 women with acromegaly. 12 women with acromegaly who completed pregnancy were identified from centres involved in the Irish Pituitary Study. 11 women had pituitary macroadenomas, one woman had a microadenoma. Only 5/17 pregnancies had optimal biochemical control of acromegaly pre-conception, as defined by IGF-1 concentration in the age related reference level and plasma GH concentration of
Source: European Journal of Endocrinology - Category: Endocrinology Authors: Tags: Eur J Endocrinol Source Type: research
AbstractPurposeThe surgical outcome on glucose metabolism in acromegaly patients is not fully understood. We aimed to investigate the impact of surgery on glucose metabolism and identify key factors that influence alterations of glucose metabolic status in acromegaly patients.MethodsOral glucose tolerance test was performed in 151 newly diagnosed acromegaly patients before and 3 –12 months after surgery. Insulin resistance and insulin secretion was assessed. Patients were grouped as cured, discordant, and having active disease according to postoperative growth hormone (GH) and insulin-like growth factor-1 (IGF-1) lev...
Source: Endocrine - Category: Endocrinology Source Type: research
More News: Acromegaly | Diabetes | Endocrinology